Comparative Efficacy of Treatment Regimens for Chronic Hepatitis D Virus Infection: A Systematic Review and Network Meta‐Analysis
Liver International · 2025
DOI: 10.1111/liv.70232 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Liver International, 2025. Verfasst von Konstantinos Ouranos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Houston Methodist Research Institute, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Interferon-alpha, Hepatitis D, Chronic, Polyethylene Glycols. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Treatment of chronic hepatitis delta virus (HDV) infection with pegylated interferon‐alpha (PEG‐IFN‐alpha) is associated with variable and often poor treatment responses. Recently, bulevirtide was approved for chronic HDV infection with promising results.
Methods
We conducted a pairwise network meta‐analysis of five treatment regimens—bulevirtide, bulevirtide plus PEG‐IFN‐alpha, PEG‐IFN‐alpha, lonafarnib and lonafarnib plus PEG‐IFN‐alpha—by reviewing randomised studies in PubMed, EMBASE and Web of Science. A control group receiving no treatment or nucleos(t)ide analogs alone was included. Primary outcomes were virological response (undetectable HDV RNA or ≥ 2 log 10 IU/mL decrease from baseline), biochemical response (ALT normalisation) and combined response (defined as fulfilment of both virological and biochemical responses), measured at end of treatment and 24 weeks post‐treatment. Odds ratios (ORs) with 95% confidence intervals (CIs) were used for analysis.
Results
Data from 934 patients in 6 randomised studies showed that, at the end of treatment, bulevirtide plus PEG‐IFN‐alpha combination therapy was more likely to achieve virological response compared to PEG‐IFN‐alpha (OR, 8.39; 95% CI: 3.46, 20.37) and bulevirtide (OR, 6.31; 95% CI: 3.17, 12.59). Bulevirtide 10 mg plus PEG‐IFN‐alpha combination therapy was more likely to achieve virological response compared to bulevirtide 2 mg plus PEG‐IFN‐alpha combination therapy at the end of treatment (OR, 2.43; 95% CI: 1.16, 5.09). Bulevirtide 10 mg (OR, 4.43; 95% CI: 1.17, 16.83) and bulevirtide 2 mg (OR, 10.95; 95% CI: 2.51, 47.74) were more likely to achieve biochemical response compared to PEG‐IFN‐alpha at the end of treatment, but bulevirtide plus PEG‐IFN‐alpha combination therapy was not (OR, 3.24; 95% CI: 0.84, 12.50). At 24 weeks post‐treatment, bulevirtide plus PEG‐IFN‐alpha combination therapy was more likely to result in virological response compared to PEG‐IFN‐alpha (OR, 3.69; 95% CI: 1.05, 12.98) and bulevirtide (OR, 2.79; 95% CI: 1.13, 6.92), as well as biochemical response compared to PEG‐IFN‐alpha (OR, 3.23; 95% CI: 1.38, 7.56). Bulevirtide plus PEG‐IFN‐alpha combination therapy was more likely to result in combined response compared to PEG‐IFN‐alpha (OR, 6.06; 95% CI: 2.03, 18.05) and bulevirtide (OR, 4.67; 95% CI: 2.21, 9.85) at the end of treatment. At 24 weeks post‐treatment, neither bulevirtide monotherapy nor bulevirtide plus PEG‐IFN‐alpha combination therapies at various doses were more likely to achieve combined response compared to PEG‐IFN‐alpha.
Conclusions
Bulevirtide plus PEG‐IFN‐alpha combination therapy was superior in achieving virological response, both in magnitude and duration, compared to bulevirtide or PEG‐IFN‐alpha monotherapies in patients with chronic HDV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Houston Methodist Research Institute, Houston, Texas, USA.
- School of Rural, Surveying and Geoinformatics Engineering, National Technical University of Athens, Athens, Greece.
- Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.
- School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece.
- Division of Gastroenterology and Hepatology, Department of Medicine, Houston Methodist Research Institute, Houston, Texas, USA.
- Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Eleftherios Mylonakis
Zitieren
APA
Ouranos, K., Mylona, E. K., Dellis, C., Bakaloudi, D. R., Shehadeh, F., Noureddin, M., Kalligeros, M., & Mylonakis, E. (2025). Comparative Efficacy of Treatment Regimens for Chronic Hepatitis D Virus Infection: A Systematic Review and Network Meta‐Analysis. Liver International. https://doi.org/10.1111/liv.70232
Vancouver
Ouranos K, Mylona EK, Dellis C, Bakaloudi DR, Shehadeh F, Noureddin M, et al. Comparative Efficacy of Treatment Regimens for Chronic Hepatitis D Virus Infection: A Systematic Review and Network Meta‐Analysis. Liver International. 2025. doi:10.1111/liv.70232
BibTeX
@article{Ouranos2025,
author = {Ouranos, Konstantinos and Mylona, Evangelia K and Dellis, Charilaos and Bakaloudi, Dimitra Rafailia and Shehadeh, Fadi and Noureddin, Mazen and Kalligeros, Markos and Mylonakis, Eleftherios},
title = {Comparative Efficacy of Treatment Regimens for Chronic Hepatitis D Virus Infection: A Systematic Review and Network Meta‐Analysis},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70232}
}
EUVIMED